All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
0.69 [0.28 ; 1.68 ] FACCT Trial, 2021 1 0% 254 NA not evaluable deathsdetailed results ChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
FACCT Trial, 2021 0.96 [0.44; 2.08]
HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89]
Zhaowei Chen, 2020 1.00 [0.02; 52.04]
1.08 [0.59 ; 2.00 ] ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, FACCT Trial, 2021, HC-nCoV (Shanghai), 2020, Zhaowei Chen, 2020 5 0% 708 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
Kamran, 2020 0.95 [0.32; 2.78]
Zhaowei Chen, 2020 0.11 [0.01; 2.19]
1.02 [0.54 ; 1.93 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, Kamran, 2020, Zhaowei Chen, 2020 3 18% 894 moderate not evaluable clinical improvement (14-day)detailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
0.83 [0.47 ; 1.44 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1 0% 448 NA not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
0.85 [0.62 ; 1.16 ] FACCT Trial, 2021 1 0% 254 NA not evaluable hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
0.88 [0.64 ; 1.21 ] FACCT Trial, 2021 1 0% 254 NA not evaluable radiologic improvement (7-day)detailed results Zhaowei Chen, 2020 3.43 [1.10; 10.70]
3.43 [1.10 ; 10.70 ] Zhaowei Chen, 2020 1 0% 62 NA not evaluable viral clearance detailed results HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75]
0.46 [0.04 ; 5.75 ] HC-nCoV (Shanghai), 2020 1 0% 30 NA not evaluable ICU admissiondetailed results FACCT Trial, 2021 1.42 [0.79; 2.55]
1.42 [0.79 ; 2.55 ] FACCT Trial, 2021 1 0% 254 NA not evaluable adverse eventsdetailed results ChiCTR2000030054-HCQ (Chen), 2020 5.00 [0.85; 29.57]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01]
1.54 [0.58 ; 4.10 ] ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 2020 3 25% 392 serious not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-01 08:10 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 90
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
